European Surgical Research
Original Paper
Metabolism in the Hypothermically Perfused Kidney: Utilization of Mevalonate in the Human and the Dog KidneyKleist H.a · Jonsson O.b · Lundstam S.c · Nauclér J.a · Pettersson S.a · Scherstén T.bDepartments of aUrology and bSurgery, Sahlgrenska Sjukhuset and cDepartment of Surgery, Östra Sjukhuset, University of Göteborg, Sweden
|
|
Log in to MyKarger to check if you already have access to this content.
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
Article / Publication Details
Received: July 07, 1981
Accepted: November 09, 1981
Published online: April 18, 2008
Issue release date: 1982
Number of Print Pages: 9
Number of Figures: 0
Number of Tables: 0
ISSN: 0014-312X (Print)
eISSN: 1421-9921 (Online)
For additional information: https://www.karger.com/ESR
Abstract
The metabolism of mevalonate was studied in 6 dog kidneys and in 5 human tumour-involved kidneys during 6 days of hypothermic perfusion. 14C-mevalonate in the perfusate decreased and was incorporated into the total lipid fraction of the cortex in both human and dog kidneys. 80 % of the incorporated radioactivity was found in the non-saponifiable lipids and after separation of that lipid fraction the radioactivity was recovered in cholesterol as well as in the cholesterol precursors lanosterol and squalene. Only very low levels of radioactivity were recovered in the tumour lipids. It is concluded that the kidney utilizes mevalonate for cholesterol synthesis during hypothermic perfusion and that addition of mevalonate may be of importance for preserving the membrane stability. Furthermore, it is suggested that hypothermic perfusion has a more deteriorating effect on the viability of the tumour tissue when compared to normal renal parenchyma.
© 1982 S. Karger AG, Basel
Related Articles:
Article / Publication Details
Received: July 07, 1981
Accepted: November 09, 1981
Published online: April 18, 2008
Issue release date: 1982
Number of Print Pages: 9
Number of Figures: 0
Number of Tables: 0
ISSN: 0014-312X (Print)
eISSN: 1421-9921 (Online)
For additional information: https://www.karger.com/ESR
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Get Permission